Gordon B. Mills
A5005221518- Cancer Genomics and Diagnostics
- PI3K/AKT/mTOR signaling in cancer
- Ovarian cancer diagnosis and treatment
- RNA modifications and cancer
- PARP inhibition in cancer therapy
- Melanoma and MAPK Pathways
- Cancer Cells and Metastasis
- Lung Cancer Treatments and Mutations
- Cancer-related Molecular Pathways
- Epigenetics and DNA Methylation
- Monoclonal and Polyclonal Antibodies Research
- Bioinformatics and Genomic Networks
- Advanced Biosensing Techniques and Applications
- HER2/EGFR in Cancer Research
- Cancer, Hypoxia, and Metabolism
- Cancer Mechanisms and Therapy
- Protein Degradation and Inhibitors
- Advanced Proteomics Techniques and Applications
- Computational Drug Discovery Methods
- Cancer, Lipids, and Metabolism
- Gene expression and cancer classification
- BRCA gene mutations in cancer
- Cancer Research and Treatments
- Advanced Breast Cancer Therapies
- Peptidase Inhibition and Analysis
Oregon Health & Science University
2018-2025
OHSU Knight Cancer Institute
2018-2025
University of Portland
2019-2024
Center for Systems Biology
2010-2023
The University of Texas MD Anderson Cancer Center
2014-2023
Huazhong University of Science and Technology
2022-2023
Tongji Hospital
2022-2023
Providence Portland Medical Center
2020-2022
University College London
2022
University of Glasgow
1998-2021
Current clinical practice is organized according to tissue or organ of origin tumors. Now, The Cancer Genome Atlas (TCGA) Research Network has started identify genomic and other molecular commonalities among a dozen different types cancer. Emerging similarities contrasts will form the basis for targeted therapies future repurposing existing by rather than histological diseases. profiled analyzed large numbers human tumors discover aberrations at DNA, RNA, protein epigenetic levels. resulting...
Infiltrating stromal and immune cells form the major fraction of normal in tumour tissue not only perturb signal molecular studies but also have an important role cancer biology. Here we describe 'Estimation STromal Immune MAlignant Tumours using Expression data' (ESTIMATE)—a method that uses gene expression signatures to infer samples. ESTIMATE scores correlate with DNA copy number-based purity across samples from 11 different types, profiled on Agilent, Affymetrix platforms or based RNA...
The Cancer Genome Atlas profiled 279 head and neck squamous cell carcinomas (HNSCCs) to provide a comprehensive landscape of somatic genomic alterations. Here we show that human-papillomavirus-associated tumours are dominated by helical domain mutations the oncogene PIK3CA, novel alterations involving loss TRAF3, amplification cycle gene E2F1. Smoking-related HNSCCs demonstrate near universal loss-of-function TP53 CDKN2A inactivation with frequent copy number including 3q26/28 11q13/22. A...
For a decade, The Cancer Genome Atlas (TCGA) program collected clinicopathologic annotation data along with multi-platform molecular profiles of more than 11,000 human tumors across 33 different cancer types. TCGA clinical contain key features representing the democratized nature collection process. To ensure proper use this large dataset associated genomic features, we developed standardized named Pan-Cancer Clinical Data Resource (TCGA-CDR), which includes four major outcome endpoints. In...
Abstract Stimulation of the insulin and insulin-like growth factor I (IGF-I) receptor activates phosphoinositide-3-kinase/Akt/mTOR pathway causing pleiotropic cellular effects including an mTOR-dependent loss in substrate-1 expression leading to feedback down-regulation signaling through pathway. In model systems, tumors exhibiting mutational activation phosphoinositide-3-kinase/Akt kinase, a common event cancers, are hypersensitive mTOR inhibitors, rapamycin. Despite activity patients,...
We conducted comprehensive integrative molecular analyses of the complete set tumors in The Cancer Genome Atlas (TCGA), consisting approximately 10,000 specimens and representing 33 types cancer. performed clustering using data on chromosome-arm-level aneuploidy, DNA hypermethylation, mRNA, miRNA expression levels reverse-phase protein arrays, which all, except for revealed primarily organized by histology, tissue type, or anatomic origin. influence cell type was evident...
Identifying molecular cancer drivers is critical for precision oncology. Multiple advanced algorithms to identify now exist, but systematic attempts combine and optimize them on large datasets are few. We report a PanCancer PanSoftware analysis spanning 9,423 tumor exomes (comprising all 33 of The Cancer Genome Atlas projects) using 26 computational tools catalog driver genes mutations. 299 with implications regarding their anatomical sites cancer/cell types. Sequence- structure-based...
Cancer progression involves the gradual loss of a differentiated phenotype and acquisition progenitor stem-cell-like features. Here, we provide novel stemness indices for assessing degree oncogenic dedifferentiation. We used an innovative one-class logistic regression (OCLR) machine-learning algorithm to extract transcriptomic epigenetic feature sets derived from non-transformed pluripotent stem cells their progeny. Using OCLR, were able identify previously undiscovered biological mechanisms...
The AACR Project GENIE is an international data-sharing consortium focused on generating evidence base for precision cancer medicine by integrating clinical-grade genomic data with clinical outcome tens of thousands patients treated at multiple institutions worldwide. In conjunction the first public release from approximately 19,000 samples, we describe goals, structure, and standards report conclusions high-level analysis initial phase data. We also provide examples utility data, such as...
Abstract Purpose: Genomic profiling studies suggest that triple-negative breast cancer (TNBC) is a heterogeneous disease. In this study, we sought to define TNBC subtypes and identify subtype-specific markers targets. Experimental Design: RNA DNA analyses were conducted on 198 tumors [estrogen receptor (ER) negativity defined as Allred scale value ≤ 2] with >50% cellularity (discovery set: n = 84; validation 114) collected at Baylor College of Medicine (Houston, TX). An external...